


09-26-05

ITW



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re U.S. Patent Application)
Applicant: Phytopharm PLC)
Serial No.: 10/507,000)
Filed: January 24, 2005)
For: THERAPEUTIC METHODS AND USES OF)
SAPOGENINS AND THEIR DERIVATIVES)

Express Mail
I hereby certify that this paper is being deposited with the United States Postal Service as ~~First Class~~ Mail in an envelope addressed to: Mail Stop ~~Pat Appl~~, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date.
9/23/05 *Quint T. Subler*
Date Registration No. 35466
Attorney for Applicant(s)

EV 731139879 US

INFORMATION DISCLOSURE STATEMENT

Mail Stop PATENT APPLICATION
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313

Sir:

Pursuant to 37 C.F.R. §1.97, a list of documents is disclosed on the attached Form PTO-1449 that may be material to the examination of this application. The cited references are enclosed herewith.

Documents for which the supplied date of publication lists the year of publication without the month were published sufficiently earlier than the effective U.S. filing date and any foreign priority date, so that the particular month of publication is not in issue. Pursuant to §609 of the MPEP, it is understood that the month of publication is not required when the particular month of publication is not in issue.

No inferences should be drawn that the attached list represents a comprehensive investigation, or that any material disclosed is equivalent to the subject invention. In


addition, none of the documents that have publication dates prior to the priority date of the above application anticipate the invention in this application.

The cited document(s) disclose numerous specific features. There has been no attempt to list each and every feature disclosed by each document. The Examiner is requested to review the document(s) and determine the extent of the materiality of the document disclosures with respect to the present invention.

The discussion of any art and the citation of any document(s) herein is not to be construed as an admission that the art or document disclosure is necessarily within the invention field of endeavor, that the art or document disclosure is necessarily prior in time to a particular date which may be relevant to the instant patent application, and/or that the art or document disclosure is otherwise necessarily prior art as defined by the patent law with respect to the instant invention and application.

Also, there is reserved the right to later set forth how the instant invention is distinguished over the disclosure of any document or other art, including the disclosures of the art and document(s) recited herein, that may be cited by the Examiner in rejecting a claim in the instant patent application. The recitation herein of the art and document(s) is not to be construed as an assertion that more pertinent art could not possibly be in existence.

Respectfully submitted,



Gerald T. Shekleton
Registration No. 27,466

Dated: September 22, 2005

WELSH & KATZ, LTD.

120 South Riverside Plaza
22nd Floor
Chicago, Illinois 60606
Telephone: 312-655-1500



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10/24/2001 W&K Substitute for Form PTO-SB/08A, which is a US PTO
Substitute for form 1449A/PTO and 1449B/PTO.**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 5

Complete if Known

Application Number	10/507,000
Filing Date	January 24, 2005
First Named Inventor	Phytopharm PLC
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	8617/92773

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	1	3,836,527			
	2	3,890,438			
	3	3,956,491			
	4	4,482,706			
	5	4,546,097			
	6	4,562,250			
	7	4,602,003			
	8	4,602,005			
	9	4,680,289			
	10	4,800,080			
	11	5,002,939			
	12	5,017,562			
	13	5,244,887			
	14	5,589,182			
	15	5,629,295			
	16	5,698,526			
	17	5,703,052			
	18	5,760,009			
	19	5,763,430			
	20	5,792,635			
	21	5,795,885			
	22	5,804,239			
	23	5,804,562			
	24	5,807,834			
	25	5,840,740			
	26	5,840,936			
	27	5,847,172			
	28	5,856,535			
	29	5,939,398			
	30	5,958,770			
	31	6,046,184			
	32	6,143,738			
	33	6,150,336			

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10/24/2001 W&K Substitute for Form PTO-SB/08A, which is a US PTO
Substitute for form 1449A/PTO and 1449B/PTO**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 5

Complete if Known

Application Number	10/507,000
Filing Date	January 24, 2005
First Named Inventor	Phytopharm PLC
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	8617/92773

34	6,258,386		
35	2001/0024666 A		
36	2001/0026814 A1		
37	2001/0029248 A1		
38	2001/0043955 A1		
39	6,593,301		
40	6,812,213		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	41	GB852847				
	42	GB2097672				
	43	EP0054570				
	44	JP58-049314				
	45	JP 62-234025				
	46	JP 02-188528				
	47	JP 02-243631				
	48	WO 91/10743				
	49	EP 0442744				
	50	WO 91/11452				
	51	WO 92/13873				
	52	JP 05-246866				
	53	DE 4303214 A1				
	54	WO 94/18994				
	55	CN 1096031A				
	56	WO 94/25017				
	57	CN 1092991A				
	58	CN 1092992A				
	59	CN 1102186A				
	60	WO 95/30341				
	61	WO 96/04296A1				
	62	EP 1 020 477 A1				
	63	JP 09-100295				
	64	FR 2 743 561				

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

10/24/2001 W&K Substitute for Form PTO-SB/08A, which is a US PTO
Substitute for form 1449A/PTO and 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	10/507,000
Filing Date	January 24, 2005
First Named Inventor	Phytopharm PLC
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	8617/92773

65	WO 97/13780				
66	WO 97/31933				
67	WO 98/51302				
68	WO 98/03180				
69	WO 98/58650				
70	WO 98/58543				
71	WO 99/09837				
72	WO 99/16449				
73	WO 99/48482				
74	GB 2 335 599 B				
75	WO 99/48507				
76	WO 99/16786				
77	CN 1212966 A				
78	EP 1 024 146 A1				
79	WO 00/61153				
80	GB 2 347 676 A				
81	WO 01/23408 A1				
82	WO 01/23407 A1				
83	WO 01/23406 A1				
84	WO 01/49703 A2				
85	WO 02/079221				
86	WO 03/082893				
87	WO 2004/037845				

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	88	Guseinov D and Iskenderov GB, "Chemical composition and biological value of saponins of some plants of Azerbaidzhan" Azerb. Med. Inst., Baku, USSR (1972)	
	89	Vich Ranova, S. A. et al., "Antiviral activity of some saponins" Trudy Vsesoyuznogo Nauchno-Issledovatel'skogo Instituta Lekarstvennykh Rastenii (1971), 14, 204-12, CAPLUS-Referat 1973: 155 107, recherchiert bei STN am 06.02.04)	
	90	Blunden G, Yi Y and Jewers K, "Steroidal Sapogenins from Leaves of Agaveae Species" Sch. Pharm., Portsmouth Polytech., UK (1979)	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10/24/2001 W&K Substitute for Form PTO-SB/08A, which is a US PTO Substitute for form 1449A/PTO and 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/507,000
				Filing Date	January 24, 2005
				First Named Inventor	Phytopharm PLC
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	4	of	5	Attorney Docket Number	8617/92773

91	Irismetov MP, Goryaev MI, Bazalitskaya VS and Kairgalieva AK, "Modified steroids. XVI. Study of the Leuckart reaction in a series of steroid compounds of solasodine and diosgenin" Inst. Khim. Nauk, Alma-Ata, USSR (1980)
92	6001 Chemical Abstracts, Columbus, Ohio US, Vol. 97 16-08-1982 No. 7 [full reference: Vopr. Med. Khim. (1982), 28(3), 101-5 (Russ)]
93	Chakravarty AK, Das B, Pakrashi SC, "Juripidine A 3 Amino Steroidal Alkaloid from Roots of Solanum-Hispidum" Phytochemistry (Oxford) (1983), pp 2843-2846
94	Schwartz RD, Lehmann J, Kellar KJ, "Presynaptic Nicotinic Cholinergic Receptors Labeled by [³ H]Acetylcholine on Catecholamine and Serotonin Axons in Brain" Journal of Neurochemistry, New York (1984), pp 1495-1498
95	Nakashima, H. et al.: Inhibitory effect of glycosides like saponin from soybean on the infectivity of HIV in vitro. AIDS 3 10 (1989) 655-658(MEDLINE-Referat 90088859, recherchiert bei STN am 06.02.04)
96	Wang S-Z, Hu J, Long RM, Pou WS, Forray C, and El-Fakahany EE, "Agonist-induced down-regulation of m1 muscarinic receptors and reduction of their mRNA level in a transfected cell line" Federation of European Biochemical Societies Letters vol. 276, no. 1,2 (1990) pp 185-188
97	Ding Y, Yi N, Wang Y, Dai X, Xia Z, "Study on the "Yin-tonic" component of the Chinese herb Zhimu: Sarsasapogenin" Hejishu (1991), 14 (5), 262-5
98	Coll PF, Rodriguez ML, Perez C, Adam G, "Steroidal compounds of Solanum antillarum O. F. Schulz. II" Rev. Cubana Quim. (1992), 6(2), 66-71
99	Fukamauchi F, Saunders PA, Hough C, and Chuang D, "Agonist-Induced Down-Regulation and Antagonist-Induced Up-Regulation of m ₂ - and m ₃ - Muscarinic Acetylcholine Receptor mRNA and Protein in Cultured Cerebellar Granule Cells" Molecular Pharmacology (1993) pp 940-949
100	He L, Hu Y, Yi N, Xia Z, "The mechanism of the regulatory action of sarsasapogenin on brain M-receptors in aged mice", Shanghai Dier Yike Daxue Xuebao 16 (5) (1996) pp 346-349
101	Hu Y, Yi N, He L, et al, "An autoradiographic study on the regional distribution of brain M-cholinergic receptors in aged rats", (1996) Chinese Journal of Gerontology, vol. 15(2)
102	Lorizzi M, DeMarino S, Minale L, Zollo F, LeBert V, Roussakis C, "Investigation of the polar steroids from an Antarctic Starfish of the family Echinasteridae: isolation of twenty seven polyhydroxysteroids and steroidal oligoglycosides, structures and biological activities.", Tetrahedron Letters vol. 52, no. 33 (1996) pp 10997-11012
103	DeNinno MP, McCarthy KE, "The ¹⁴ C Radiolabelled Synthesis of the Cholesterol Absorption Inhibitor CP-148, 623. A Novel Method for the Incorporation of a ¹⁴ C Label in Enones", Tetrahedron Letters vol. 53, no. 32 (1997) pp 11007-11020

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10/24/2001 W&K Substitute for Form PTO-SB/08A, which is a US PTO Substitute for form 1449A/PTO and 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/507,000
		Filing Date	January 24, 2005
		First Named Inventor	Phytopharm PLC
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet 5 of 5	Attorney Docket Number	8617/92773	

104	Yi N, Hu Y, Xia Z, "Sarsasapogenin: Mechanism in Treating Senile Dementia", Synthesis and Applications of Isotopically Labelled Compounds (1997) pp 315-320	
105	Yi N, Hu Y, Xia Z, "The Mechanism of a Sapogenin from Anemarrhenae Asphodeloides BGE in the Treatment of Senile Dementia", Collection of Abstract prepared for the 6 th International Symposium of the International Isotope Society, Philadelphia, 14-18 September 1997, p103	
106	DeNinno P, McCarthy PA, Duplantier KC, Eller C, et al, "Steroidal Glycoside Cholesterol Absorption Inhibitors", Journal of Medicinal Chemistry (1997) vol. 40, pp 2547-2554	
107	Chang ZL, Puhl HL, May LG, Williams CL, and Aronstam RS, "Influence of Acute and Chronic Ethanol Treatment on Muscarinic Responses and Receptor Expression in Chinese Hamster Ovary Cells", Biochem. Pharmacol. vol. 54,7 pp 834-839 (1997)	
108	Kinoshita K, Akiba M, Saitoh M, Ye Y, Koyama K, Takahashi K, Kondo N, and Yuasa H, "Antinociceptive Effect of Triterpenes from Cacti", Pharmaceutical Biology vol. 36, no. 1 (1998) pp 50-57.	
109	Fukamauchi F, Wang Y-J, Chuang D-M, "Ethanol Induces Subtype-Specific Up-Regulation of Muscarinic Acetylcholine Receptor mRNA in Neurohybrid Cell Lines", Life Sciences, vol. 62, no. 5 (1997) pp 389-396	
110	Rahman, A-U, Choudhary MI, Asif F, Farooq A, Yaqoob M, and Dar A, "Microbial Transformation of Sarsasapogenin by Fusarium Lini", Phytochemistry vol. 49, no. 8 (1998) pp 2341-2342	
111	Sramek JJ, Forrest M, Mengel H, Jhee SS, Hourani J, and Cutler NR, "A Bridging Study of Lu 25-109 in Patients with Probable Alzheimer's Disease", Life Sciences vol. 62, no. 3 (1998) pp 195-202	
112	Shi, J., et al.: 'The regulation effect of sarsasapogenin on M2 receptor density in CHO M2 cell' <i>Acta Universitatis Medicinalis Secundae Shanghai</i> 20 no. 6 (2000), 503-505	
113	Yi Ningyu et al.: 'Extraction of .beta.-adrenergic receptor- and M cholinergic receptor-regulating (.beta.-, 5.beta.,25s)-spirostan-3-ol from Anemarrhena asphodeloides Bunge' Abstract XP002168420	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.